Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science



Rating:

Share or cite this content

Citations should be made in the following way:
E. Israel (Boston, United States of America), A. Menzies-Gow (London, United Kingdom), G. Chupp (New Haven, United States of America), C. Ambrose (Gaithersburg, United States of America), B. Cook (Gaithersburg, United States of America), G. Hunter (Cambridge, United Kingdom), J. Llanos-Ackert (Thousand Oaks, United States of America), J. Downie (Thousand Oaks, United States of America), G. Colice (Gaithersburg, United States of America). Efficacy of tezepelumab in adolescents with severe, uncontrolled asthma. 1490

Member's Comments

No comment yet.

Related content which might interest you: Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021 Management of difficult-to-treat severe asthma Source: Eur Respir Mon 2011; 51: 282-296 Year: 2011 Mepolizumab for severe eosinophilic asthma: a comparison of efficacy in children, adolescents, and adults Source: International Congress 2018 – New developments in paediatric asthma Year: 2018 Management of severe asthma in children Source: Virtual Congress 2020 – Reducing the burden of asthma Year: 2020 Management of severe asthma in children Source: Annual Congress 2010 - ERS/[italic]Lancet[/italic] Asthma Year: 2010 Management of severe asthma in children Source: International Congress 2018 – ME11 Management of severe asthma in children FULLY BOOKED Year: 2018 ME11 Management of severe asthma in children Source: Paris 2018 - Educational material Year: 2018 Factors resulting in uncontrolled severe persistent asthma in children Source: Eur Respir J 2004; 24: Suppl. 48, 20s Year: 2004 Severe asthma in children Source: CME Online 2011 Year: 2011 Severe asthma in children Source: International Congress 2015 – Fingerprinting severe asthma Year: 2015 Risk factors for severe exacerbations in a real-life population of adults with severe refractory asthma Source: International Congress 2017 – Many faces of asthma and allergies Year: 2017 Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Tezepelumab efficacy in patients with severe, uncontrolled asthma and comorbid nasal polyps in NAVIGATOR Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Efficacy of montelukast in Indian patients having chronic persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 372s Year: 2003 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Efficacy of ruzam in the treatment of patients with mild-to-moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma Source: Eur Respir J, 55 (1) 1900964; 10.1183/13993003.00964-2019 Year: 2020 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Predictors of severe asthma exacerbations, poor asthma control and beta-agonist overuse in adult asthma Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013